Johnson & Johnson (ETR:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 355.15B |
| Revenue (ttm) | 77.35B |
| Net Income (ttm) | 19.34B |
| Shares Out | n/a |
| EPS (ttm) | 7.97 |
| PE Ratio | 18.36 |
| Forward PE | 15.70 |
| Dividend | 4.62 (3.13%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 3,514 |
| Average Volume | 3,659 |
| Open | 147.70 |
| Previous Close | 147.02 |
| Day's Range | 145.98 - 147.88 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | 0.40 |
| RSI | 70.23 |
| Earnings Date | Jul 16, 2025 |
About Activision Blizzard
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsNews
Why Johnson & Johnson Stock Still Has Room To Run
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
The 3 Things That Matter for Johnson & Johnson Now
Can the stock still deliver the same kinds of returns it has over the past few decades?
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will participate in a Fireside Chat at 11:30 a....
Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will part...
Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case
BOSTON--(BUSINESS WIRE)--A Boston jury has sided with Paul and Kathryn Lovell in a lawsuit against cosmetic behemoth Johnson & Johnson (NYSE:JNJ) that asserted Mr. Lovell's mesothelioma was directly c...
Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch
Regulatory News: Medincell (Paris:MEDCL): Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA, a...
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1 ,2 , *,** WEST CHESTER, Penn. , July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Joh...
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA ® , the only dual-acting IL-23 inhibitor HORSHAM, Pa. , July ...
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA ® , the only dual-acting IL-23 inhibitor HORSHAM, Pa. , July 29, ...
22 Dividend Kings At Discounted Valuations
Dividend kings can offer reliable income growth and capital appreciation, making them attractive for long-term investors. During our screening today, we have 22 dividend kings trading at what could be...
20 Kiplinger July Dividend Favorites: No Cigars
Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to d...
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ: PLTR) Foundry platform, highl...
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in ...
US FDA says J&J's Ethicon issues correction related to surgical stapler
The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "...